News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bevacizumab Linked to Higher Mortality Risk, Stony Brook University Medical Center Study



2/2/2011 6:56:05 AM

MedPageToday -- Cancer patients treated with the angiogenesis inhibitor bevacizumab (Avastin) had almost 50% more fatal adverse events compared with control groups, data from a meta-analysis of 10,000 patients showed. The 16 studies included in the analysis had a 2.5% cumulative incidence of fatal events in bevacizumab-treated patients compared with 1.7% among patients treated with regimens that did not include the targeted agent.

Read at MedPageToday


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES